Worth It?
What’s the value of a trusting relationship with a good doctor? A life-altering medication? Choices among medical treatments? These and other thorny questions took center stage at the Alliance for Patient Access and Institute for Patient Access’ first-ever leadership retreat, held last week in San Diego.
“Well Beyond Blue” Meeting Allows Patients to Voice Perspective
An upcoming meeting will give people with movement disorders a chance to tell Food and Drug Administration regulators their story – the story of their physical symptoms as well as their emotional ones.
Infant Health Summit Highlights Need for Access, Nutrition & Safety
Advocates cannot reach every infant or every family, acknowledged National Coalition for Infant Health Medical Director Mitchell Goldstein, MD, as he welcomed attendees to the fourth annual infant health policy summit on Thursday.
What Price Reductions for Cholesterol-lowering Medications Mean for Patients
Patient advocates across the country cheered this week as news spread about a decrease in the list price of evolocumab.
Poll: Parents Lack Awareness of Deadly RSV Virus
Parents of young children lack knowledge about a potentially deadly seasonal virus, a new survey from the National Coalition for Infant Health reveals.
Comments on Draft Evidence Report for Severe Asthma Therapies
Mitigating the high cost of severe asthma requires, in part, access to the appropriate medications. Those include the five monoclonal antibodies indicated for the treatment of patients with moderate to severe asthma that were reviewed in this draft evidence report. These medicines are clinically effective, as the report notes. Specifically, the report cites that the […]
ICER’s Asthma Report Comes up Short
It’s plagued by incomplete analysis and missing data, yet the Institute for Clinical and Economic Review’s draft evidence report on severe asthma medicine still manages to deliver a familiar refrain. All five of the drugs reviewed, ICER reports, are not cost-effective.
ICER Asthma Social Graphics
Living with Gout and Chronic Kidney Disease
They cost me a promising college basketball career, my second toe and, for a while, my self-esteem. But gout and chronic kidney disease haven’t stopped me from leading a full life. And they shouldn’t hold others back either.
Can ICER Put a Price on Asthma Control?
The Institute for Clinical and Economic Review says new medicine for uncontrolled asthma isn’t worth its cost. But its analysis omits key details. View the Graphic. View Social Graphics.
